RIVM European Reference Lab for vector-borne infections The European Commission (EC) has designated RIVM as the current European Reference Lab (EURL) for vector-borne viral pathogens.
Menno de Jong appointed director of RIVM Centre for Infectious Disease Control Starting 1 May 2024, Professor Menno de Jong will take on the role of director of RIVM’s Centre for Infectious Disease Control (CIb) . He succeeds Jaap van Dissel, who is retiring in April 2024.
Metabolic disorder ALD added to newborn blood spot screening Since 1 October, the metabolic disorder adrenoleukodystrophy (ALD) has been added to the Dutch newborn blood spot screening. From now on, the blood of newborn boys will also be tested for this disorder. ALD in boys can be treated if it is detected in time.
From 1 October 2023, heel prick test also screens for metabolic disorder ALD From 1 October 2023, the blood of newborn babies will also be tested for the metabolic disorder adrenoleukodystrophy (ALD). This is done with the heel prick screening test.
NIPT available as standard option for all pregnant women from 1 April From 1 April 2023, the Non-Invasive Prenatal Test (NIPT) will be available to all pregnant women. They do not have to take part in a scientific study for this.
Urgent need for more research into environmental effects of microplastics Additional solutions are urgently needed to limit emissions of microplastics into the environment. Growing quantities of microplastics (particles of 5 mm or less) are entering our living environment every day.
Antibiotic use and antimicrobial resistance remain stable Antibiotic resistance in the Netherlands remained stable in 2021 compared with the five previous years. This is evident from the 2022 annual NethMap/MARAN report.
Current knowledge on microplastics in the soil is still inadequate A literature review carried out by the National Institute for Public Health and the Environment (RIVM) has concluded that reliable standard techniques should be developed to analyse microplastics in the soil.
From 1 June 2022, heel prick test also screens for muscle disease SMA, bringing number of screened diseases to 26 From 1 June 2022, the heel prick test for Dutch newborns will also screen for spinal muscular atrophy (SMA). SMA is a serious hereditary muscle condition. Detecting this disease at an early stage enables early treatment.
Can healthy gut microbes protect us against antibiotic-resistant bacteria? It is largely assumed within the scientific community that a healthy intestinal microbiome can provide resistance against the settling, growth and multiplication of antibiotic-resistant bacteria.